Retension Pharmaceuticals Inc.
RTSNHealthcare|Medical - Pharmaceuticals|US
$11.04
+0.32 (+2.99%)
Clinical Trials (3)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07142356 A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension | Uncontrolled Hypertension | P2 | Recruiting | 280 | RCT, Double-blind | RTN-001, Matching placebo control |
| NCT00562549 Safety and Effects of SLx-2101 Taken for up to 14 Days on Blood Pressure in Patients With Hypertension | Hypertension | P2 | Completed | 26 | RCT, Double-blind | SLx-2101 |
| NCT00562614 Safety and Effect of Oral Doses of 5mg or 10mg of SLx-2101 for 14 Days in Patients With Hypertension | Hypertension | P2 | Completed | 38 | RCT, Double-blind | SLx-2101 |